Ligand Pharmaceuticals (LGND) Amortization - Intangibles (2015 - 2026)

Over the trailing twelve months to Jun 30, 2026, Ligand Pharmaceuticals reported Amortization - Intangibles of $32.39 million, down 2.1% year-over-year; for FY2025, it came in at $32.71 million, down 0.9% from FY2024.

• Amortization - Intangibles has declined in each of the last three years, though with a five-year compound annual growth rate of 22.9% (FY2020 to FY2025).
• Going back by year, Amortization - Intangibles was $33 million in FY2024 (-2.1%), $33.7 million in FY2023 (-1.6%), $34.24 million in FY2022 (unchanged) and $34.22 million in FY2021 (+194.0%).
• The five-year range for quarterly Amortization - Intangibles is -$1.17 million (Q4 2021) to $11.83 million (Q3 2021).
• Year-over-year, Amortization - Intangibles has declined for four consecutive quarters, with an average decline of 1.0% over the last eight quarters.
• The fastest year-over-year change in Amortization - Intangibles over five years came in Q3 2021 (growth of 205.2%), and the weakest in Q3 2022 (a decline of 27.6%).
• Business Quant data shows LGND's Amortization - Intangibles at $8.1 million (Q1 2026), $8.1 million (Q4 2025) and $8.1 million (Q3 2025) in the three quarters before Q2 2026.